{"title":"法理大学医院儿科重症监护病房鲍曼不动杆菌感染的流行及危险因素","authors":"Pornumpa Bunjoungmanee, Kornkamon Rattanapan, Yamonbhorn Neamkul, Auchara Tangsathapornpong, Narissara Mungkornkaew, Prapasri Kulalert","doi":"10.12688/f1000research.157612.3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong><i>Acinetobacter baumannii</i> infection (ABI) is a concerning worldwide public health matter with high levels of morbidity and mortality, particularly in critically ill patients. This study aims to assess the prevalence, risk factors, and clinical outcomes of ABI in the pediatric intensive care unit (PICU) setting.</p><p><strong>Methods: </strong>A retrospective review was performed on pediatric patients admitted to the PICU over an 8-year period. Demographic characteristics, infection risk factors, and clinical outcomes were compared and analyzed between patients with ABI, determined to be the case group, and patients without ABI, determined to be the control group. The study also assessed the prevalence of ABI and its antimicrobial resistance profile.</p><p><strong>Results: </strong>Between June 2014 and May 2022, a total of 82 cases of ABI were identified, resulting in an overall prevalence of 5.02%. After applying the exclusion criteria, 12 cases were excluded. Consequently, 70 ABI cases in total and 140 cases in a control group were included in the study. Multivariable conditional logistic regression analysis identified chronic respiratory disease, mechanical ventilation lasting 5 days or more, and the use of piperacillin/tazobactam within the last 2 weeks as independent risk factors associated with ABI. The rate of carbapenem-resistant <i>A. baumannii</i> (CRAB) was notably high at 94.26%. Cases of ABI were associated with higher mortality rates and prolonged hospitalization compared to non-ABI cases.</p><p><strong>Conclusion: </strong>ABI remains a critical pathogen in the PICU. The presence of chronic respiratory disease, use of mechanical ventilation for at least five days, and a history of receiving piperacillin/tazobactam within the last 2 weeks are significant risk factors for ABI. The high level of antibiotic resistance, especially to carbapenems, highlights the emphasis for more stringent infection control practices and the creation of novel antimicrobial therapies.</p>","PeriodicalId":12260,"journal":{"name":"F1000Research","volume":"13 ","pages":"1269"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125569/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prevalence and risk factors of <i>Acinetobacter baumannii</i> infection in Pediatric Intensive Care Unit at Thammasat University Hospital.\",\"authors\":\"Pornumpa Bunjoungmanee, Kornkamon Rattanapan, Yamonbhorn Neamkul, Auchara Tangsathapornpong, Narissara Mungkornkaew, Prapasri Kulalert\",\"doi\":\"10.12688/f1000research.157612.3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong><i>Acinetobacter baumannii</i> infection (ABI) is a concerning worldwide public health matter with high levels of morbidity and mortality, particularly in critically ill patients. This study aims to assess the prevalence, risk factors, and clinical outcomes of ABI in the pediatric intensive care unit (PICU) setting.</p><p><strong>Methods: </strong>A retrospective review was performed on pediatric patients admitted to the PICU over an 8-year period. Demographic characteristics, infection risk factors, and clinical outcomes were compared and analyzed between patients with ABI, determined to be the case group, and patients without ABI, determined to be the control group. The study also assessed the prevalence of ABI and its antimicrobial resistance profile.</p><p><strong>Results: </strong>Between June 2014 and May 2022, a total of 82 cases of ABI were identified, resulting in an overall prevalence of 5.02%. After applying the exclusion criteria, 12 cases were excluded. Consequently, 70 ABI cases in total and 140 cases in a control group were included in the study. Multivariable conditional logistic regression analysis identified chronic respiratory disease, mechanical ventilation lasting 5 days or more, and the use of piperacillin/tazobactam within the last 2 weeks as independent risk factors associated with ABI. The rate of carbapenem-resistant <i>A. baumannii</i> (CRAB) was notably high at 94.26%. Cases of ABI were associated with higher mortality rates and prolonged hospitalization compared to non-ABI cases.</p><p><strong>Conclusion: </strong>ABI remains a critical pathogen in the PICU. The presence of chronic respiratory disease, use of mechanical ventilation for at least five days, and a history of receiving piperacillin/tazobactam within the last 2 weeks are significant risk factors for ABI. The high level of antibiotic resistance, especially to carbapenems, highlights the emphasis for more stringent infection control practices and the creation of novel antimicrobial therapies.</p>\",\"PeriodicalId\":12260,\"journal\":{\"name\":\"F1000Research\",\"volume\":\"13 \",\"pages\":\"1269\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125569/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"F1000Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12688/f1000research.157612.3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/f1000research.157612.3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Prevalence and risk factors of Acinetobacter baumannii infection in Pediatric Intensive Care Unit at Thammasat University Hospital.
Background: Acinetobacter baumannii infection (ABI) is a concerning worldwide public health matter with high levels of morbidity and mortality, particularly in critically ill patients. This study aims to assess the prevalence, risk factors, and clinical outcomes of ABI in the pediatric intensive care unit (PICU) setting.
Methods: A retrospective review was performed on pediatric patients admitted to the PICU over an 8-year period. Demographic characteristics, infection risk factors, and clinical outcomes were compared and analyzed between patients with ABI, determined to be the case group, and patients without ABI, determined to be the control group. The study also assessed the prevalence of ABI and its antimicrobial resistance profile.
Results: Between June 2014 and May 2022, a total of 82 cases of ABI were identified, resulting in an overall prevalence of 5.02%. After applying the exclusion criteria, 12 cases were excluded. Consequently, 70 ABI cases in total and 140 cases in a control group were included in the study. Multivariable conditional logistic regression analysis identified chronic respiratory disease, mechanical ventilation lasting 5 days or more, and the use of piperacillin/tazobactam within the last 2 weeks as independent risk factors associated with ABI. The rate of carbapenem-resistant A. baumannii (CRAB) was notably high at 94.26%. Cases of ABI were associated with higher mortality rates and prolonged hospitalization compared to non-ABI cases.
Conclusion: ABI remains a critical pathogen in the PICU. The presence of chronic respiratory disease, use of mechanical ventilation for at least five days, and a history of receiving piperacillin/tazobactam within the last 2 weeks are significant risk factors for ABI. The high level of antibiotic resistance, especially to carbapenems, highlights the emphasis for more stringent infection control practices and the creation of novel antimicrobial therapies.
F1000ResearchPharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
5.00
自引率
0.00%
发文量
1646
审稿时长
1 weeks
期刊介绍：
F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
